Hybrid Androgen Receptor Inhibitors Outperform Enzalutamide and EPI‐001 in in vitro Models of Prostate Cancer Drug Resistance

Androgen receptor targeted therapies for prostate cancer have serious limitations in advanced stages of the disease. While resistance to the FDA‐approved enzalutamide is extensively documented, novel therapies based on epichlorohydrin scaffolds (EPI) are currently in clinical trials, but display sub...

Descripción completa

Detalles Bibliográficos
Autores principales: Nicolescu, Radu Costin Bizga, Maylin, Zoe R., Pérez‐Areales, Francisco Javier, Iegre, Jessica, Pandha, Hardev S., Asim, Mohammad, Spring, David R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098645/
https://www.ncbi.nlm.nih.gov/pubmed/36300876
http://dx.doi.org/10.1002/cmdc.202200548

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10098645/
https://www.ncbi.nlm.nih.gov/pubmed/36300876
http://dx.doi.org/10.1002/cmdc.202200548

Ejemplares similares